Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech pushes back Avastin deadline

DNA postponed its plans to stop selling Avastin bevacizumab to compounding pharmacies. The

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE